Clinical trial · Observational
Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer
NCT01277562CI-TRIAL-00018204completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators hypothesis is that secondary causes of bone loss are prevalent in patients with breast and prostate cancer, and those patients with secondary causes of bone loss are at higher risk for treatment related bone loss. The goals of this pilot study are to estimate the prevalence of secondary causes of osteoporosis in a cohort of patients with nonmetastatic breast and prostate cancer with osteopenia and osteoporosis.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Osteopenia | — | UNRESOLVED | — |
| Osteoporosis | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Breast Cancer
- description
- Non-metastatic breast cancer with recent diagnosis of osteopenia or osteoporosis
- label
- Prostate Cancer
- description
- Non-metastatic prostate cancer with recent diagnosis of osteopenia or osteoporosis
Primary outcomes (1)
- measure
- Determine prevalence of secondary causes of bone loss in patients with new diagnosis of osteopenia/o
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria 1. Diagnosis of nonmetastatic breast cancer or diagnosis of nonmetastatic prostate cancer 2. Measurement of bone mineral density by Dual Energy X-ray Absorptiometry (DEXA) within 6 months of enrollment into study. 3. Patients of all ages are eligible but need to qualify for standard DEXA screening 4. Patients of all performance status are eligible 5. Patients are able to give informed consent Exclusion Criteria 1. Patients previously diagnosed or treated for osteoporosis/osteopenia 2. Stage IV cancer
References
Publications (0)
Data not yet available
No reference posted for this study.